Developer docs
API playgroundTry for free, no card

Search company profiles

X-tosis

Full company profile

uuid002qj1x

Namestring
X-tosis
Legal namestring
X-tosis, Inc.
Websiteurl
x-tosis.com
Company typeenum
Private
Founded yearint
2024
Descriptiontext

X-tosis, Inc. is a privately held, pre-clinical precision-medicine biotechnology company founded in 2024 and headquartered in Gainesville, Florida. The company is developing first-in-class small-molecule therapeutics designed to restore mitochondrial function and prevent neuronal death in patients with neurodegenerative diseases, beginning with Parkinson's disease (via lead candidate XTS001) and extending to Alzheimer's disease, ALS, and related conditions characterized by mitochondrial dysfunction.

The company's core technology is the patented MitoXTS platform, a family of small-molecule inhibitors of VDAC1 (voltage-dependent anion channel 1) oligomerization. By stabilizing VDAC1 on the outer mitochondrial membrane, XTS compounds aim to preserve mitochondrial membrane potential, reduce reactive oxygen species, limit release of apoptotic factors, and interrupt inflammatory cascades, constituting an upstream, disease-modifying approach as opposed to symptomatic management. The platform is grounded in more than five decades of research led by Professor Varda Shoshan-Barmatz (225+ publications, 14,000+ citations) and is supported by precision biomarkers intended to guide patient selection, treatment, and monitoring. Patent protection extends through at least 2036.

X-tosis operates a partnership-driven business model: the company pursues out-licensing and pharmaceutical partnerships for development and commercialization of XTS compounds across multiple indications rather than building its own commercial infrastructure. Non-dilutive grant funding is a primary capital source, including a $2.74 million award from The Michael J. Fox Foundation for Parkinson's Research (June 2026) earmarked for advancing XTS001 through IND-enabling studies. The company supplements pipeline development with active conference presence (Biotech Showcase Seed Showcase 2025 and the J.P. Morgan Annual Healthcare Conference) to attract pharma partners and investors. The company has no product revenue and is pre-commercial, with pricing structure to be determined upon FDA approval.

Short descriptiontext

X-tosis is a pre-clinical precision-medicine biotechnology company developing first-in-class small-molecule mitochondrial therapeutics that inhibit VDAC1 oligomerization to treat neurodegenerative diseases including Parkinson's and Alzheimer's, advancing assets via licensing and pharmaceutical partnerships.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersGainesville, United States
HQ citystring
Gainesville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
mitochondrial therapeutics, neurodegenerative disease treatment, Alzheimer's drug development, Parkinson's disease therapy, precision medicine biotechnology
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Biotechnology Therapeutics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Licensing and Partnership Revenue
TypeLicensing Royalties
Description

X-tosis is a pre-clinical biotech pursuing licensing opportunities for multiple indications. The company plans to partner with pharmaceutical companies for development and commercialization of XTS compounds. Licensing opportunities are available for multiple indications.

x-tosis.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1MitoXTS
Description

A patented family of small-molecule inhibitors of voltage-dependent anion channel 1 (VDAC1) oligomerization, representing the company's core therapeutic platform technology.

x-tosis.com
Core offering1 text field

X-tosis develops first-in-class small-molecule therapeutics that selectively inhibit VDAC1 (voltage-dependent anion channel 1) oligomerization through its patented MitoXTS™ platform to restore mitochondrial function, reduce inflammation, and prevent neuronal death. The company is advancing its lead candidate XTS001, a brain-penetrant oral small molecule, through preclinical and IND-enabling studies targeting Parkinson's disease, Alzheimer's disease, ALS, and related neurodegenerative conditions, complemented by precision biomarkers for patient selection and treatment monitoring.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • Robust efficacy in Alzheimer's and Parkinson's preclinical models including reductions in neuronal loss, improvements in cognitive function, restoration of mitochondrial activity, and mitigation of inflammation
+6 more records
Product overview1 text field

X-tosis is a precision-medicine biotechnology company developing first-in-class mitochondrial therapeutics through its patented MitoXTS™ platform. The platform centers on XTS compounds (including lead candidate XTS001), which are small-molecule inhibitors of VDAC1 oligomerization designed to restore mitochondrial function and prevent neuronal death across neurodegenerative diseases including Alzheimer's, Parkinson's, and ALS. The company also employs precision biomarkers for patient selection and monitoring. Founded in 2024 and based in Gainesville, FL, X-tosis's approach is built on over two decades of research by Professor Varda Shoshan-Barmatz.

Product and service4 records
1MitoXTS™ Platform
CategoryTherapeutic Platform
Description

A patented family of small-molecule inhibitors of voltage-dependent anion channel 1 (VDAC1) oligomerization designed to restore mitochondrial function, reduce inflammation, and prevent neuronal death for neurodegenerative disease treatment. The platform is licensed to pharmaceutical partners across multiple indications.

2XTS001
CategoryDrug Candidate
Description

Lead brain-penetrant, orally available small molecule drug candidate that selectively inhibits VDAC1 oligomerization for the treatment of Parkinson's disease and other neurodegenerative conditions. Demonstrated in preclinical models to reduce neuronal loss, restore dopamine levels, preserve mitochondrial function, and protect against PD-associated pathologies.

3XTS Compounds
CategoryDrug Candidates
Description

First-in-class mitochondrial therapeutics that target mitochondrial dysfunction by inhibiting VDAC1 oligomerization, applicable across multiple neurodegenerative diseases including Alzheimer's, Parkinson's, and ALS. Available for licensing and partnership opportunities across multiple indications.

4Precision Biomarkers
CategoryDiagnostic Tool
Description

Biomarkers used for patient selection, treatment guidance, and monitoring as part of the company's precision medicine approach to neurodegenerative disease treatment.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Public clinical-stage biotech with a broad neurodegenerative and lysosomal storage disease pipeline, including BBB-penetrant small molecules. Comparable as a well-capitalized developer of disease-modifying CNS therapeutics, though operating at much larger scale across multiple targets.

2Stealth BioTherapeutics
TypeDirect peer
Description

Clinical-stage company developing mitochondria-targeted therapeutics (elamipretide and pipeline candidates) for diseases involving mitochondrial dysfunction, including neurological and metabolic indications. Most directly comparable peer given shared focus on small-molecule mitochondrial modulators.

TypeDirect peer
Description

UK-based clinical-stage biotech developing small-molecule mitophagy inducers and deubiquitinase inhibitors relevant to mitochondrial and neurological diseases. Comparable as a small-molecule developer addressing mitochondrial and CNS pathology.

TypeEmerging player
Description

Clinical-stage biotech developing CNS therapeutics for neurodegenerative diseases including dementia with Lewy bodies and Parkinson's. Comparable as a small-cap clinical-stage CNS drug developer pursuing neurodegenerative indications.

TypeEmerging player
Description

Clinical-stage biotech developing small-molecule therapeutics targeting bacterial virulence and neurodegeneration for Alzheimer's disease. Comparable as a small-molecule disease-modifying CNS developer.

TypeDirect peer
Description

Clinical-stage pharmaceutical company developing small-molecule therapies that target mitochondrial dysfunction for inherited mitochondrial diseases and related neurological conditions. Closely aligned in modality (small molecules), target (mitochondria), and therapeutic area (neurology).

TypeEmerging player
Description

Clinical-stage biotech developing small-molecule therapeutics for neurodegenerative diseases including Alzheimer's and Parkinson's. Comparable as a small-cap CNS-focused drug developer pursuing disease-modifying mechanisms.

TypeEmerging player
Description

Private biotechnology company developing precision therapies for mitochondrial diseases using small molecules and biologics. Comparable as a venture-backed platform mitochondrial therapeutics company pursuing multiple indications.

TypeBroad incumbent
Description

Clinical-stage biotech developing protein-targeted therapeutics for neurodegenerative diseases including Parkinson's and ALS. Comparable as a CNS-focused biotech pursuing disease-modifying approaches, though working in biologics rather than small molecules.

TypeDirect peer
Description

Swedish clinical-stage biotech developing mitochondrial medicine for primary mitochondrial disease and neurological indications. Directly comparable as a small-cap mitochondrial therapeutics developer pursuing CNS and rare disease applications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

X-tosis

Biotechnology Therapeuticsx-tosis.com

X-tosis is a pre-clinical precision-medicine biotechnology company developing first-in-class small-molecule mitochondrial therapeutics that inhibit VDAC1 oligomerization to treat neurodegenerative diseases including Parkinson's and Alzheimer's, advancing assets via licensing and pharmaceutical partnerships.

What X-tosis does

X-tosis, Inc. is a privately held, pre-clinical precision-medicine biotechnology company founded in 2024 and headquartered in Gainesville, Florida. The company is developing first-in-class small-molecule therapeutics designed to restore mitochondrial function and prevent neuronal death in patients with neurodegenerative diseases, beginning with Parkinson's disease (via lead candidate XTS001) and extending to Alzheimer's disease, ALS, and related conditions characterized by mitochondrial dysfunction.

The company's core technology is the patented MitoXTS platform, a family of small-molecule inhibitors of VDAC1 (voltage-dependent anion channel 1) oligomerization. By stabilizing VDAC1 on the outer mitochondrial membrane, XTS compounds aim to preserve mitochondrial membrane potential, reduce reactive oxygen species, limit release of apoptotic factors, and interrupt inflammatory cascades, constituting an upstream, disease-modifying approach as opposed to symptomatic management. The platform is grounded in more than five decades of research led by Professor Varda Shoshan-Barmatz (225+ publications, 14,000+ citations) and is supported by precision biomarkers intended to guide patient selection, treatment, and monitoring. Patent protection extends through at least 2036.

X-tosis operates a partnership-driven business model: the company pursues out-licensing and pharmaceutical partnerships for development and commercialization of XTS compounds across multiple indications rather than building its own commercial infrastructure. Non-dilutive grant funding is a primary capital source, including a $2.74 million award from The Michael J. Fox Foundation for Parkinson's Research (June 2026) earmarked for advancing XTS001 through IND-enabling studies. The company supplements pipeline development with active conference presence (Biotech Showcase Seed Showcase 2025 and the J.P. Morgan Annual Healthcare Conference) to attract pharma partners and investors. The company has no product revenue and is pre-commercial, with pricing structure to be determined upon FDA approval.

X-tosis firmographics

Firmographics
Name
X-tosis
Legal name
X-tosis, Inc.
Website
https://x-tosis.com
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
1–10 employees
Short description
X-tosis is a pre-clinical precision-medicine biotechnology company developing first-in-class small-molecule mitochondrial therapeutics that inhibit VDAC1 oligomerization to treat neurodegenerative diseases including Parkinson's and Alzheimer's, advancing assets via licensing and pharmaceutical partnerships.
Ownership category
akta.pro rank

Where X-tosis is headquartered

Location

Headquarters

HQ city
Gainesville
HQ country
United States
HQ region
North America

Offices1 record

Markets served

X-tosis business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Licensing and Partnership Revenue: X-tosis is a pre-clinical biotech pursuing licensing opportunities for multiple indications. The company plans to partner with pharmaceutical companies for development and commercialization of XTS compounds. Licensing opportunities are available for multiple indications.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

X-tosis product offering

Product offering

Core offering

X-tosis develops first-in-class small-molecule therapeutics that selectively inhibit VDAC1 (voltage-dependent anion channel 1) oligomerization through its patented MitoXTS™ platform to restore mitochondrial function, reduce inflammation, and prevent neuronal death. The company is advancing its lead candidate XTS001, a brain-penetrant oral small molecule, through preclinical and IND-enabling studies targeting Parkinson's disease, Alzheimer's disease, ALS, and related neurodegenerative conditions, complemented by precision biomarkers for patient selection and treatment monitoring.

Product overview

X-tosis is a precision-medicine biotechnology company developing first-in-class mitochondrial therapeutics through its patented MitoXTS™ platform. The platform centers on XTS compounds (including lead candidate XTS001), which are small-molecule inhibitors of VDAC1 oligomerization designed to restore mitochondrial function and prevent neuronal death across neurodegenerative diseases including Alzheimer's, Parkinson's, and ALS. The company also employs precision biomarkers for patient selection and monitoring. Founded in 2024 and based in Gainesville, FL, X-tosis's approach is built on over two decades of research by Professor Varda Shoshan-Barmatz.

Differentiator

Problem solved

Functional benefit

Brands

  • MitoXTS: A patented family of small-molecule inhibitors of voltage-dependent anion channel 1 (VDAC1) oligomerization, representing the company's core therapeutic platform technology.

Products and services

  • MitoXTS™ Platform A patented family of small-molecule inhibitors of voltage-dependent anion channel 1 (VDAC1) oligomerization designed to restore mitochondrial function, reduce inflammation, and prevent neuronal death for neurodegenerative disease treatment. The platform is licensed to pharmaceutical partners across multiple indications.
  • XTS001 Lead brain-penetrant, orally available small molecule drug candidate that selectively inhibits VDAC1 oligomerization for the treatment of Parkinson's disease and other neurodegenerative conditions. Demonstrated in preclinical models to reduce neuronal loss, restore dopamine levels, preserve mitochondrial function, and protect against PD-associated pathologies.
  • XTS Compounds First-in-class mitochondrial therapeutics that target mitochondrial dysfunction by inhibiting VDAC1 oligomerization, applicable across multiple neurodegenerative diseases including Alzheimer's, Parkinson's, and ALS. Available for licensing and partnership opportunities across multiple indications.
  • Precision Biomarkers Biomarkers used for patient selection, treatment guidance, and monitoring as part of the company's precision medicine approach to neurodegenerative disease treatment.

Quantifiable outcome

  • Robust efficacy in Alzheimer's and Parkinson's preclinical models including reductions in neuronal loss, improvements in cognitive function, restoration of mitochondrial activity, and mitigation of inflammation
  • +6 more outcomes

Companies that use X-tosis

Customer profile

Segments1 record

Ideal customer profiles3 records

X-tosis technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

X-tosis partnerships and signals

Strategic signal

Scale indicators8 records

Recent moves4 records

Expansion highlights5 records

X-tosis competitors and assessment

Company assessment

Broad incumbents

  • Denali Therapeutics: Public clinical-stage biotech with a broad neurodegenerative and lysosomal storage disease pipeline, including BBB-penetrant small molecules. Comparable as a well-capitalized developer of disease-modifying CNS therapeutics, though operating at much larger scale across multiple targets.
  • Prothena Corporation: Clinical-stage biotech developing protein-targeted therapeutics for neurodegenerative diseases including Parkinson's and ALS. Comparable as a CNS-focused biotech pursuing disease-modifying approaches, though working in biologics rather than small molecules.

Direct peers

  • Stealth BioTherapeutics: Clinical-stage company developing mitochondria-targeted therapeutics (elamipretide and pipeline candidates) for diseases involving mitochondrial dysfunction, including neurological and metabolic indications. Most directly comparable peer given shared focus on small-molecule mitochondrial modulators.
  • Mission Therapeutics: UK-based clinical-stage biotech developing small-molecule mitophagy inducers and deubiquitinase inhibitors relevant to mitochondrial and neurological diseases. Comparable as a small-molecule developer addressing mitochondrial and CNS pathology.
  • Khondrion BV: Clinical-stage pharmaceutical company developing small-molecule therapies that target mitochondrial dysfunction for inherited mitochondrial diseases and related neurological conditions. Closely aligned in modality (small molecules), target (mitochondria), and therapeutic area (neurology).
  • Abliva AB: Swedish clinical-stage biotech developing mitochondrial medicine for primary mitochondrial disease and neurological indications. Directly comparable as a small-cap mitochondrial therapeutics developer pursuing CNS and rare disease applications.

Emerging players

  • CervoMed (formerly Neuraly): Clinical-stage biotech developing CNS therapeutics for neurodegenerative diseases including dementia with Lewy bodies and Parkinson's. Comparable as a small-cap clinical-stage CNS drug developer pursuing neurodegenerative indications.
  • Cortexyme: Clinical-stage biotech developing small-molecule therapeutics targeting bacterial virulence and neurodegeneration for Alzheimer's disease. Comparable as a small-molecule disease-modifying CNS developer.
  • Annovis Bio: Clinical-stage biotech developing small-molecule therapeutics for neurodegenerative diseases including Alzheimer's and Parkinson's. Comparable as a small-cap CNS-focused drug developer pursuing disease-modifying mechanisms.
  • Pretzel Therapeutics: Private biotechnology company developing precision therapies for mitochondrial diseases using small molecules and biologics. Comparable as a venture-backed platform mitochondrial therapeutics company pursuing multiple indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

X-tosis social profiles

Digital presence

X-tosis financial estimates

Financial estimate

Revenue estimate

Valuation estimate

X-tosis leadership team

Management profile

Number of profiles

Profiles12 records

X-tosis funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

X-tosis M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about X-tosis

What does X-tosis do?

X-tosis develops first-in-class small-molecule therapeutics that selectively inhibit VDAC1 (voltage-dependent anion channel 1) oligomerization through its patented MitoXTS™ platform to restore mitochondrial function, reduce inflammation, and prevent neuronal death. The company is advancing its lead candidate XTS001, a brain-penetrant oral small molecule, through preclinical and IND-enabling studies targeting Parkinson's disease, Alzheimer's disease, ALS, and related neurodegenerative conditions, complemented by precision biomarkers for patient selection and treatment monitoring.

Is X-tosis a public or private company?

X-tosis is a private company. It is classified as venture growth investor backed and is currently operating.

When was X-tosis founded?

X-tosis was founded in 2024. It employs 1 to 10 people.

Where is X-tosis based?

X-tosis is headquartered in Gainesville, United States, in the North America region.

How does X-tosis make money?

One revenue line is on record: licensing and Partnership Revenue.

Who are X-tosis's main competitors?

Broad incumbents on record are Denali Therapeutics and Prothena Corporation. Direct peers are Stealth BioTherapeutics, Mission Therapeutics, Khondrion BV and Abliva AB. Emerging players are CervoMed (formerly Neuraly), Cortexyme, Annovis Bio and Pretzel Therapeutics.

Does X-tosis have an API?

No public API is recorded for X-tosis.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals